EXPERIMENTAL IMMUNOLOGY
Myrrh and artesunate modulate some Th1 and Th2 cytokines secretion in Schistosoma mansoni infected mice
Submission date: 2015-12-17
Final revision date: 2016-02-10
Acceptance date: 2016-02-10
Publication date: 2016-07-15
Cent Eur J Immunol 2016;41(2):138-142
KEYWORDS
ABSTRACT
The effects of artesunate and myrrh on S. mansoni infection and the levels of some Th1 and Th2 cytokines were evaluated in the present study. Six weeks after infection, a group of mice was treated with 4 mg/kg of artesunate and other group was treated with 10 mg/kg of myrrh for 3 successive days. Worm burden was reduced with a percentage of 53.7 % and 58.78 % after treatment with myrrh and artesunate respectively as well as the levels of IgG antibodies were significantly reduced compared with infected group. No obvious changes were observed in the level of interferon after treatment. After treatment with artesunate, interleukin 2 (IL-2) level was significantly decreased, while no significant difference was observed in myrrh-treated group compared with the infected group. On the other hand, the level of IL-10 was not significantly decreased after treatment with artesunate, but it was significantly increased after treatment with myrrh. However, IL-12 levels were significantly decreased after treatment with artesunate. The results demonstrated that, artesunate or myrrh treatment could give a level of protection against S. mansoni infection and modulate the levels of some Th1 and Th2 cytokines in mice infected with S. mansoni.
REFERENCES (34)
1.
El Ridi RAF, Tallima H (2013): Novel therapeutic and prevention approaches for schistosomiasis. J Adv Res 4: 467-478.
2.
Tonkal AM, Morsy TA (2008): An update review on Commiphora molmol and related species. J Egypt Soc Parasitol 38: 763-796.
3.
Badria F, Abou-Mohamad G, El-Mowafi A, et al. (2001): Mirazid: a new schistosomicidal drug. Pharma Biol 39: 127-131.
4.
Osman MM, El-Taweel HA, Shehab AY, Farag HF (2010): Ineffectiveness of myrrh-derivative Mirazid against schistosomiasis and fascioliasis in humans. East Mediterr Health J 16: 932-936.
5.
Fathy FM (2011): Anthelmintic effect of artesunate in experimental heterophyid infection. J Egypt Soc Parasitol 41: 469-483.
6.
Xiao SH, Catto BA (1989): In vitro and in vivo studies of the effect of artemether on Schistosoma mansoni. Antimicrob Agents Chemother 33: 1557-1562.
7.
Abdul-Ghani R, Loutfi N, Sheta M, Hassan A (2011): Artemether shows promising female schistosomicidal and ovicidal effects on the Egyptian strain of Schistosoma mansoni after maturity of infection. Parasitol Res 108: 1199-1205.
8.
Rutitzky LI, Hernandez HJ, Yim YS, et al. (2005): Enhanced egg-induced immunopathology correlates with high IFN-gamma in murine schistosomiasis: identification of two epistatic genetic intervals. J Immunol 174: 435-440.
9.
Salem ML, Shoukry NM, Zidan AA, Vournakis J (2014): Immunomodulatory effects of IL-12 released from poly-N-acetyl glucosamine gel matrix during schistosomiasis infection. Cytotechnology 66: 667-675.
10.
Margaret M, Kane M, Cheever A, et al. (2014): Accelerated, Progressive, and Lethal Liver Fibrosis in Mice that Lack Interleukin (IL)-10, IL-12p40, and IL-13R 2. Gastroenterol 2014; 141: 2200-2209.
11.
Hesse M, Piccirillo CA, Belkaid Y, et al. (2004): The pathogenesis of schistosomiasis is controlled by cooperating IL-10-producing innate effector and regulatory T cells. J Immunol 172: 3157-3166.
12.
McKee AS, Pearce EJ (2004): CD25+CD4+ cells contribute to Th2 polarization during helminth infection by suppressing Th1 response development. J Immunol 2004; 173: 1224-1231.
13.
Kane CM, Cervi L, Sun J, et al. (2004): Helminth antigens modulate TLR-initiated dendritic cell activation. J Immunol 173: 7454-7461.
14.
Duvall RH, DeWitt WB (1967): An improved perfusion technique for recovering adult schistosomes from laboratory animals. Am J Trop Med Hyg 16: 483-486.
15.
Attalah AM, Abdel Aziz M, Abbas AT, et al. (2004): Vaccination of mice with a 30 kDa Schistosoma antigen with and without adjuvant induces high protection against S. mansoni infection. J Helminthol 2004; 78: 189-194.
16.
King CH, Dickman K, Tisch DJ (2003): Reassessment of the cost of chronic schistosome infection in sub-Saharan Africa. Acta Trop 86: 125-139.
17.
Soliman OE, EL-Arman M, Abdul-Samie ER, et al. (2004): Evaluation of myrrh (Mirazid) therapy in fascioliasis and intestinal schistosomiasis in children: immunological and parasitological study. J Egypt Soc Parasitol 34: 941-966.
18.
ABO-Madyan AA, Morsy TA, Motawea SM (2004): Efficacy of myrrh in the treatment of Schistosomiasis (haematobium and mansoni) in Ezbet El-Bakly, Tamyia Center, El-Fayoum Governorate. Egypt J Egypt Soc Parasitol 34: 423-426.
19.
Botros S, William S, Ebeid F, et al. (2004): Lack of evidence for an antischistosomal activity of myrrh in experimental animals. Am J Trop Hyg 71: 206-210.
20.
Barakat R, EL-Morshedy H, Fenwick A (2005): Efficacy of myrrh in the treatment of human schistosomiasis mansoni. Am J Trop Med Hyg 73: 365-367.
21.
Abdel-Aziz M, Abbas AT, Elbakry KA, et al. (2006): Immune response on mice infected with Schistosoma mansoni and treated with myrrh. J Med Sci 6: 858-861.
22.
Lotfy WM, Nageh AM, Hussein NA, Hassan AA (2013): Application and evaluation of a molecular approach for detection of the schistosomicidal effect of Mirazid® (myrrh) in the murine model. J Adv Res 4: 563-567.
23.
Vaillant B, Chiaramonte MG, Cheever AW, et al. (2001): Regulation of hepatic fibrosis and extracellular matrix genes by the th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol 167: 7017-7026.
24.
Hoffmann KF, Wynn TA, Dunne DW. Cytokine-mediated host responses during schistosome infections; walking the fine line between immunological control and immunopathology. Adv Parasitol 2002; 52: 265-307.
25.
Rutitzky LI, Hernandez HJ, Stadecker MJ (2001): Th1-polarizing immunization with egg antigens correlates with severe exacerbation of immunopathology and death in schistosome infection. Proc Natl Acad Sci 98: 13243-1328.
26.
Rutitzky LI, Mirkin GA, Stadecker MJ (2003): Apoptosis by neglect of CD4+ Th cells in granulomas: a novel effector mechanism involved in the control of egg-induced immunopathology in murine schistosomiasis. J Immunol 171: 1859-1867.
27.
Hoffmann KF, Cheever AW, Wynn TA (2000): IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. Immunol 164: 6406.
28.
Leptak CL, McKerrow JH (1997): Schistosome egg granulomas and hepatic expression of TNF-αlpha are dependent on immune priming during parasite maturation. J Immunol 158: 301-307.
29.
Wynn TA, Cheever A, Williams M, et al. (1998): IL-10 regulates liver pathology in acute murine Schistosomiasis mansoni but is not required for immune down-modulation of chronic disease. J Immunol 1998; 160: 4473.
30.
Iacomini J, Ricklan D, Stadecker M (1995): T cells expressing the gd T cell receptor are not required for egg granuloma formation in schistosomiasis. Eur J Immunol 25: 884-888.
31.
Henri S, Chevillard C, Mergani A, et al. (2002): Cytokine regulation of periportal fibrosis in humans infected with Schistosoma mansoni: IFN-gamma is associated with protection against fibrosis and TNF-αlpha with aggravation of disease. J Immunol 169: 929-936.
32.
Booth M, Mwatha JK, Joseph S, et al. (2004): Periportal fibrosis inhuman Schistosoma mansoni infection is associated with low IL-10, lowIFN-, high TNF, or low rantes, depending on age and gender. J Immunol 172: 1295-1203.
33.
Ribeiro de Jesus, A, Magalhaes A, Miranda DG, et al. (2004): Association of type 2 cytokines with hepatic fibrosis inhuman Schistosoma mansoni infection. Infect Immun 72: 3391-3397.
34.
Montenegro SM, Miranda P, Mahanty S, et al. (1999): Cytokine production in acuteversus chronic human schistosomiasis mansoni: the cross-regulatory role ofinterferon-_ and interleukin-10 in the responses of peripheral blood mononuclearcells and splenocytes to parasite antigens. J Infect Dis 179: 1502-1514.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
